Nutriband Key Executives
This section highlights Nutriband's key executives, including their titles and compensation details.
Find Contacts at Nutriband
(Showing 0 of )
Nutriband Earnings
This section highlights Nutriband's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
$5.84
Stock Price
$64.86M
Market Cap
2.02K
Employees
Orlando, FL
Location
Financial Statements
Access annual & quarterly financial statements for Nutriband, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | January 31, 2024 | January 31, 2023 | January 31, 2022 | January 31, 2021 | January 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.09M | $2.08M | $1.42M | $943.70K | $370.65K |
| Cost of Revenue | $1.22M | $1.33M | $917.84K | $582.38K | $549.11K |
| Gross Profit | $862.11K | $750.41K | $504.31K | $361.32K | $-178.46K |
| Gross Profit Ratio | 41.34% | 36.08% | 35.46% | 38.29% | -48.15% |
| Research and Development Expenses | $1.96M | $982.23K | $411.38K | $- | $- |
| General and Administrative Expenses | $- | $- | $4.02M | $2.91M | $- |
| Selling and Marketing Expenses | $- | $- | $- | $45.00K | $- |
| Selling General and Administrative Expenses | $3.77M | $3.92M | $4.02M | $2.96M | $1.79M |
| Other Expenses | $- | $327.33K | $2.18M | $- | $- |
| Operating Expenses | $5.73M | $4.90M | $4.43M | $2.96M | $1.79M |
| Cost and Expenses | $6.96M | $6.23M | $5.35M | $3.54M | $2.34M |
| Interest Income | $16.85K | $8.29K | $118.42K | $280.69K | $73.41K |
| Interest Expense | $75.81K | $8.29K | $118.42K | $280.69K | $73.41K |
| Depreciation and Amortization | $287.72K | $368.96K | $318.26K | $169.72K | $91.84K |
| EBITDA | $-5.12M | $-4.11M | $-5.74M | $-2.48M | $-2.56M |
| EBITDA Ratio | -245.61% | -197.45% | -403.57% | -263.05% | -689.71% |
| Operating Income | $-4.87M | $-4.15M | $-3.93M | $-2.60M | $-1.97M |
| Operating Income Ratio | -233.63% | -199.45% | -276.33% | -275.08% | -531.35% |
| Total Other Income Expenses Net | $-613.39K | $-335.62K | $-2.25M | $-336.88K | $-752.19K |
| Income Before Tax | $-5.49M | $-4.48M | $-6.18M | $-2.93M | $-2.72M |
| Income Before Tax Ratio | -263.04% | -215.59% | -434.28% | -310.78% | -734.29% |
| Income Tax Expense | $- | $327.33K | $2.25M | $280.69K | $73.41K |
| Net Income | $-5.49M | $-4.81M | $-8.42M | $-3.21M | $-2.80M |
| Net Income Ratio | -263.04% | -231.33% | -592.23% | -340.52% | -754.10% |
| EPS | $-0.69 | $-0.57 | $-1.06 | $-0.48 | $-0.44 |
| EPS Diluted | $-0.69 | $-0.57 | $-1.06 | $-0.48 | $-0.44 |
| Weighted Average Shares Outstanding | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M |
| Weighted Average Shares Outstanding Diluted | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 | January 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $645.80K | $442.83K | $408.53K | $524.61K | $427.84K | $655.93K | $476.93K | $527.53K | $618.00K | $456.15K | $477.92K | $491.89K | $283.04K | $213.74K | $433.49K | $348.09K | $391.80K | $84.45K | $119.36K | $19.58K |
| Cost of Revenue | $454.77K | $341.27K | $254.32K | $354.39K | $268.92K | $356.26K | $254.65K | $398.14K | $349.27K | $304.35K | $277.44K | $388.54K | $173.69K | $186.76K | $168.84K | $161.73K | $228.77K | $116.94K | $74.94K | $126.23K |
| Gross Profit | $191.03K | $101.56K | $154.21K | $170.22K | $158.92K | $299.67K | $222.28K | $129.40K | $268.73K | $151.80K | $200.49K | $103.35K | $109.34K | $26.98K | $264.64K | $186.36K | $163.03K | $-32.49K | $44.42K | $-106.65K |
| Gross Profit Ratio | 29.58% | 22.93% | 37.75% | 32.45% | 37.14% | 45.69% | 46.61% | 24.53% | 43.48% | 33.28% | 41.95% | 21.01% | 38.63% | 12.62% | 61.05% | 53.54% | 41.61% | -38.47% | 37.22% | -544.78% |
| Research and Development Expenses | $880.77K | $773.98K | $974.53K | $563.37K | $551.50K | $445.12K | $400.43K | $295.83K | $290.72K | $277.87K | $117.81K | $250.38K | $161.00K | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $1.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $737.10K | $737.33K | $1.07M | $913.20K | $1.33M | $678.74K | $839.73K | $1.19M | $1.05M | $908.17K | $768.55K | $1.45M | $1.49M | $509.22K | $579.61K | $2.37M | $203.98K | $193.33K | $191.92K | $509.44K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $327.33K | $- | $- | $- | $2.18M | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $1.62M | $1.51M | $2.04M | $1.48M | $1.88M | $1.12M | $1.24M | $1.81M | $1.34M | $1.19M | $886.37K | $1.70M | $1.65M | $509.22K | $579.61K | $2.37M | $203.98K | $193.33K | $191.92K | $509.44K |
| Cost and Expenses | $2.07M | $1.85M | $2.30M | $1.83M | $2.15M | $1.48M | $1.49M | $2.21M | $1.69M | $1.49M | $1.16M | $2.09M | $1.82M | $695.98K | $748.45K | $2.53M | $432.75K | $310.27K | $266.86K | $635.67K |
| Interest Income | $68.23K | $77.33K | $18 | $3.02K | $3.77K | $4.25K | $5.82K | $4.22K | $3.97K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $4.03K | $5.02K | $8.62K | $23.21K | $40.20K | $9.23K | $3.17K | $- | $3.97K | $4.43K | $4.11K | $3.15K | $33.38K | $41.02K | $40.87K | $73.85K | $1.62K | $51 | $205.17K | $71.85K |
| Depreciation and Amortization | $73.15K | $69.95K | $69.10K | $69.34K | $67.87K | $83.16K | $83.05K | $70.45K | $112.39K | $93.65K | $92.46K | $82.88K | $79.56K | $79.56K | $76.26K | $76.55K | $47.47K | $22.85K | $22.85K | $22.85K |
| EBITDA | $-1.29M | $-1.63M | $-1.82M | $-1.79M | $-1.65M | $-744.63K | $-936.86K | $-1.61M | $-959.13K | $-940.59K | $-593.42K | $-3.68M | $-1.46M | $-399.34K | $-198.83K | $-2.10M | $6.52K | $-202.97K | $-184.18K | $-849.29K |
| EBITDA Ratio | -199.05% | -368.20% | -445.59% | -340.90% | -386.10% | -113.52% | -196.44% | -305.78% | -155.20% | -206.20% | -124.17% | -748.62% | -515.44% | -186.84% | -45.87% | -603.81% | 1.66% | -240.34% | -154.30% | -4338.23% |
| Operating Income | $-1.43M | $-1.41M | $-1.89M | $-1.31M | $-1.72M | $-824.19K | $-1.02M | $-1.68M | $-1.07M | $-1.03M | $-685.88K | $-3.78M | $-1.54M | $-482.24K | $-314.96K | $-2.18M | $-40.95K | $-225.82K | $-147.49K | $-616.09K |
| Operating Income Ratio | -220.94% | -318.35% | -462.50% | -249.01% | -402.84% | -125.65% | -213.42% | -319.13% | -173.38% | -226.73% | -143.51% | -767.47% | -543.55% | -225.62% | -72.66% | -626.76% | -10.45% | -267.40% | -123.56% | -3147.02% |
| Total Other Income Expenses Net | $64.20K | $-295.72K | $-8.60K | $-574.62K | $-36.44K | $-4.99K | $2.65K | $4.22K | $-3.97K | $-4.43K | $-4.11K | $6.66K | $-33.38K | $-37.68K | $-993 | $-70.51K | $-1.62K | $-51 | $-264.70K | $-328.34K |
| Income Before Tax | $-1.36M | $-1.71M | $-1.90M | $-1.88M | $-1.76M | $-829.17K | $-1.02M | $-1.68M | $-1.08M | $-1.04M | $-689.99K | $-3.77M | $-1.57M | $-519.92K | $-315.96K | $-2.25M | $-42.57K | $-225.87K | $-412.19K | $-944.43K |
| Income Before Tax Ratio | -211.00% | -385.13% | -464.61% | -358.54% | -411.36% | -126.41% | -212.87% | -318.33% | -174.03% | -227.71% | -144.37% | -766.11% | -555.34% | -243.25% | -72.89% | -647.01% | -10.87% | -267.46% | -345.33% | -4824.21% |
| Income Tax Expense | $- | $- | $-1 | $-8.53K | $3.77K | $4.25K | $517 | $- | $3.97K | $4.43K | $4.11K | $2.17M | $33.38K | $41.02K | $40.87K | $73.85K | $- | $- | $205.17K | $71.85K |
| Net Income | $-1.36M | $-1.71M | $-1.90M | $-1.88M | $-1.76M | $-829.17K | $-1.02M | $-1.68M | $-1.08M | $-1.04M | $-694.10K | $-3.77M | $-1.57M | $-519.92K | $-315.96K | $-2.25M | $-42.57K | $-225.87K | $-412.19K | $-944.43K |
| Net Income Ratio | -211.00% | -385.13% | -464.61% | -358.54% | -411.36% | -126.41% | -212.98% | -318.33% | -174.67% | -228.68% | -145.23% | -766.11% | -555.34% | -243.25% | -72.89% | -647.01% | -10.87% | -267.46% | -345.33% | -4824.21% |
| EPS | $-0.12 | $-0.15 | $-0.21 | $-0.23 | $-0.22 | $-0.11 | $-0.13 | $0.00 | $-0.14 | $-0.11 | $-0.08 | $-0.50 | $-0.21 | $-0.06 | $-0.04 | $-0.35 | $-0.01 | $-0.04 | $-0.06 | $-0.15 |
| EPS Diluted | $-0.12 | $-0.15 | $-0.21 | $-0.23 | $-0.22 | $-0.11 | $-0.13 | $0.00 | $-0.14 | $-0.11 | $-0.08 | $-0.50 | $-0.21 | $-0.06 | $-0.04 | $-0.35 | $-0.01 | $-0.04 | $-0.06 | $-0.15 |
| Weighted Average Shares Outstanding | 11.10M | 11.06M | 9.16M | 8.20M | 7.83M | 7.83M | 7.83M | - | 7.80M | 9.81M | 9.18M | 7.59M | 7.59M | 8.65M | 7.38M | 6.43M | 6.44M | 6.43M | 6.38M | 6.33M |
| Weighted Average Shares Outstanding Diluted | 11.10M | 11.06M | 9.16M | 8.20M | 7.83M | 7.83M | 7.83M | - | 7.80M | 9.81M | 9.18M | 7.59M | 7.59M | 8.65M | 7.38M | 6.43M | 6.44M | 6.43M | 6.38M | 6.33M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | January 31, 2024 | January 31, 2023 | January 31, 2022 | January 31, 2021 | January 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $492.94K | $1.99M | $4.89M | $151.99K | $10.18K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $492.94K | $1.99M | $4.89M | $151.99K | $10.18K |
| Net Receivables | $148.65K | $113.05K | $71.38K | $109.35K | $12.83K |
| Inventory | $168.60K | $229.34K | $131.65K | $52.85K | $0 |
| Other Current Assets | $211.67K | $365.93K | $740.94K | $- | $20.17K |
| Total Current Assets | $1.02M | $2.69M | $5.47M | $314.19K | $43.18K |
| Property Plant Equipment Net | $806.30K | $960.49K | $998.34K | $1.08M | $120.64K |
| Goodwill | $5.02M | $5.02M | $5.35M | $7.53M | $1.72M |
| Intangible Assets | $667.28K | $780.43K | $926.91K | $1.01M | $314.70K |
| Goodwill and Intangible Assets | $5.69M | $5.80M | $6.28M | $8.54M | $2.03M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $-6.76M | $-7.27M | $- | $-2.15M |
| Total Non-Current Assets | $6.50M | $6.76M | $7.27M | $9.61M | $2.15M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $7.52M | $9.46M | $12.74M | $9.93M | $2.20M |
| Account Payables | $680.13K | $534.68K | $639.54K | $940.61K | $771.93K |
| Short Term Debt | $161.46K | $82.32K | $52.78K | $1.57M | $321.62K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $157.50K | $162.90K | $106.27K | $86.85K | $- |
| Other Current Liabilities | $1 | $-256.78K | $-164.26K | $-161.07K | $928.77K |
| Total Current Liabilities | $999.09K | $748.61K | $779.26K | $2.57M | $2.02M |
| Long Term Debt | $79.83K | $134.77K | $101.12K | $343.67K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $-96.80K | $- |
| Total Non-Current Liabilities | $79.83K | $134.77K | $101.12K | $246.87K | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.08M | $883.39K | $880.38K | $2.82M | $2.02M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $8.86K | $7.83K | $7.84K | $6.26K | $5.44K |
| Retained Earnings | $-27.98M | $-22.49M | $-18.01M | $-11.84M | $-8.90M |
| Accumulated Other Comprehensive Income Loss | $-304 | $-304 | $-304 | $-304 | $-304 |
| Other Total Stockholders Equity | $34.41M | $31.06M | $29.86M | $18.94M | $9.07M |
| Total Stockholders Equity | $6.44M | $8.57M | $11.86M | $7.11M | $175.43K |
| Total Equity | $6.44M | $8.57M | $11.86M | $7.11M | $175.43K |
| Total Liabilities and Stockholders Equity | $7.52M | $9.46M | $12.74M | $9.93M | $2.20M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $7.52M | $9.46M | $12.74M | $9.93M | $2.20M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $241.28K | $185.81K | $134.57K | $1.79M | $321.62K |
| Net Debt | $-251.66K | $-1.80M | $-4.76M | $1.64M | $311.44K |
Balance Sheet Charts
| Breakdown | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 | January 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.70M | $6.76M | $8.35M | $492.94K | $1.27M | $2.33M | $1.28M | $1.99M | $2.82M | $3.34M | $4.01M | $4.89M | $5.49M | $304.26K | $410.75K | $151.99K | $193.39K | $39.25K | $20.64K | $10.18K |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $5.70M | $6.76M | $8.35M | $492.94K | $1.27M | $2.33M | $1.28M | $1.99M | $2.82M | $3.34M | $4.01M | $4.89M | $5.49M | $304.26K | $410.75K | $151.99K | $193.39K | $39.25K | $20.64K | $10.18K |
| Net Receivables | $109.63K | $68.01K | $85.14K | $148.65K | $169.67K | $223.45K | $164.64K | $113.05K | $80.45K | $146.56K | $99.10K | $71.38K | $146.41K | $13.77K | $150.81K | $109.35K | $90.66K | $14.64K | $39.64K | $12.83K |
| Inventory | $168.30K | $223.86K | $168.50K | $168.60K | $174.64K | $156.92K | $181.50K | $229.34K | $184.32K | $161.83K | $127.53K | $131.65K | $124.94K | $72.60K | $90.27K | $52.85K | $39.21K | $- | $- | $0 |
| Other Current Assets | $215.49K | $196.24K | $128.55K | $211.67K | $780.21K | $558.65K | $369.28K | $365.93K | $426.11K | $461.01K | $404.64K | $740.94K | $191.82K | $432.25K | $282.54K | $- | $- | $73.05K | $6.42K | $20.17K |
| Total Current Assets | $6.19M | $7.25M | $8.73M | $1.02M | $2.00M | $3.27M | $1.99M | $2.69M | $3.51M | $4.11M | $4.64M | $5.47M | $5.95M | $606.75K | $934.37K | $314.19K | $323.26K | $90.42K | $66.70K | $43.18K |
| Property Plant Equipment Net | $747.47K | $753.22K | $763.83K | $806.30K | $806.06K | $853.49K | $908.35K | $960.49K | $1.00M | $1.06M | $1.10M | $998.34K | $990.00K | $1.04M | $1.07M | $1.08M | $1.28M | $93.47K | $107.06K | $120.64K |
| Goodwill | $5.02M | $5.02M | $5.02M | $5.02M | $5.02M | $5.02M | $5.02M | $5.02M | $5.35M | $5.35M | $5.35M | $5.35M | $7.53M | $7.53M | $7.53M | $7.53M | $8.19M | $1.72M | $1.72M | $1.72M |
| Intangible Assets | $582.42K | $610.71K | $638.99K | $667.28K | $695.57K | $723.86K | $752.14K | $780.43K | $808.72K | $862.00K | $894.47K | $926.91K | $959.37K | $991.82K | $1.02M | $1.01M | $286.90K | $296.17K | $305.43K | $314.70K |
| Goodwill and Intangible Assets | $5.60M | $5.63M | $5.66M | $5.69M | $5.72M | $5.75M | $5.77M | $5.80M | $6.16M | $6.21M | $6.24M | $6.28M | $8.49M | $8.52M | $8.55M | $8.54M | $8.47M | $2.02M | $2.02M | $2.03M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $- | $-6.60M | $-6.68M | $- | $- | $-7.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Assets | $6.35M | $6.39M | $6.42M | $6.50M | $6.52M | $6.60M | $6.68M | $6.76M | $7.16M | $7.27M | $7.34M | $7.27M | $9.48M | $9.56M | $9.63M | $9.61M | $9.76M | $2.11M | $2.13M | $2.15M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-10 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $12.54M | $13.63M | $15.15M | $7.52M | $8.52M | $9.87M | $8.68M | $9.46M | $10.67M | $11.39M | $11.98M | $12.74M | $15.43M | $10.16M | $10.56M | $9.93M | $10.08M | $2.20M | $2.20M | $2.20M |
| Account Payables | $- | $778.83K | $994.11K | $680.13K | $387.86K | $496.78K | $543.75K | $- | $535.84K | $620.86K | $535.44K | $639.54K | $644.54K | $975.60K | $873.99K | $940.61K | $811.77K | $733.47K | $712.13K | $771.93K |
| Short Term Debt | $136.76K | $162.72K | $179.40K | $195.74K | $193.92K | $192.21K | $83.95K | $51.03K | $82.51K | $56.67K | $91.52K | $52.78K | $226.18K | $1.64M | $1.60M | $1.57M | $1.62M | $104.57K | $13.78K | $321.62K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $218.87K | $179.58K | $269.35K | $157.50K | $169.50K | $217.89K | $188.70K | $162.90K | $201.99K | $145.91K | $129.99K | $106.27K | $239.58K | $64.70K | $69.89K | $86.85K | $118.02K | $29.73K | $-712.13K | $- |
| Other Current Liabilities | $892.15K | $-17.53K | $-347.31K | $-260.33K | $-33.51K | $-316.14K | $-284.73K | $534.68K | $-293.75K | $-204.49K | $-231.64K | $-164.26K | $-106.03K | $-141.22K | $-145.25K | $-161.07K | $- | $- | $- | $928.77K |
| Total Current Liabilities | $1.25M | $1.10M | $1.42M | $999.09K | $717.77K | $874.13K | $784.39K | $748.61K | $789.75K | $803.92K | $723.06K | $779.26K | $1.00M | $2.66M | $2.52M | $2.57M | $2.55M | $867.76K | $725.90K | $2.02M |
| Long Term Debt | $63.72K | $69.13K | $374.51K | $79.83K | $2.09M | $2.11M | $171.43K | $134.77K | $147.88K | $181.32K | $131.14K | $101.12K | $104.60K | $167.71K | $292.37K | $343.67K | $272.11K | $34.87K | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $50.18K | $- | $- | $24.22K | $-90.38K | $-96.80K | $- | $- | $- | $- |
| Total Non-Current Liabilities | $63.72K | $69.13K | $374.51K | $79.83K | $2.09M | $2.11M | $171.43K | $134.77K | $147.88K | $181.32K | $181.32K | $101.12K | $104.60K | $191.93K | $201.99K | $246.87K | $272.11K | $34.87K | $- | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.31M | $1.17M | $1.79M | $1.08M | $2.81M | $2.98M | $955.82K | $883.39K | $937.63K | $985.24K | $904.38K | $880.38K | $1.11M | $2.85M | $2.72M | $2.82M | $2.83M | $902.63K | $725.90K | $2.02M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $11.11K | $11.10K | $10.96K | $8.86K | $7.83K | $7.83K | $7.83K | $7.83K | $7.80K | $7.80K | $7.82K | $7.84K | $7.74K | $6.36K | $6.36K | $6.26K | $6.13K | $5.52K | $5.51K | $5.44K |
| Retained Earnings | $-32.95M | $-31.58M | $-29.88M | $-27.98M | $-26.10M | $-24.34M | $-23.51M | $-22.49M | $-20.82M | $-19.74M | $-18.70M | $-18.01M | $-14.24M | $-12.67M | $-12.15M | $-11.84M | $-9.58M | $-9.54M | $-9.31M | $-8.90M |
| Accumulated Other Comprehensive Income Loss | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 | $-304 |
| Other Total Stockholders Equity | $44.17M | $44.03M | $43.23M | $34.41M | $31.80M | $31.22M | $31.22M | $31.06M | $30.54M | $30.13M | $29.77M | $29.86M | $28.55M | $19.98M | $19.98M | $18.94M | $16.83M | $10.83M | $10.78M | $9.07M |
| Total Stockholders Equity | $11.23M | $12.46M | $13.36M | $6.44M | $5.71M | $6.89M | $7.72M | $8.57M | $9.73M | $10.40M | $11.08M | $11.86M | $14.32M | $7.32M | $7.84M | $7.11M | $7.25M | $1.30M | $1.47M | $175.43K |
| Total Equity | $11.23M | $12.46M | $13.36M | $6.44M | $5.71M | $6.89M | $7.72M | $8.57M | $9.73M | $10.40M | $11.08M | $11.86M | $14.32M | $7.32M | $7.84M | $7.11M | $7.25M | $1.30M | $1.47M | $175.43K |
| Total Liabilities and Stockholders Equity | $12.54M | $13.63M | $15.15M | $7.52M | $8.52M | $9.87M | $8.68M | $9.46M | $10.67M | $11.39M | $11.98M | $12.74M | $15.43M | $10.16M | $10.56M | $9.93M | $10.08M | $2.20M | $2.20M | $2.20M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.54M | $13.63M | $15.15M | $7.52M | $8.52M | $9.87M | $8.68M | $9.46M | $10.67M | $11.39M | $11.98M | $12.74M | $15.43M | $10.16M | $10.56M | $9.93M | $10.08M | $2.20M | $2.20M | $2.20M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $200.48K | $214.32K | $527.92K | $241.28K | $2.25M | $2.27M | $223.37K | $185.81K | $199.80K | $218.47K | $238.95K | $134.57K | $224.75K | $1.81M | $1.78M | $1.79M | $1.90M | $139.44K | $13.78K | $321.62K |
| Net Debt | $-5.50M | $-6.55M | $-7.82M | $-251.66K | $989.06K | $-67.30K | $-1.05M | $-1.80M | $-2.62M | $-3.13M | $-3.77M | $-4.76M | $-5.26M | $1.50M | $1.37M | $1.64M | $1.70M | $100.19K | $-6.87K | $311.44K |
Annual Cash Flow
| Breakdown | January 31, 2024 | January 31, 2023 | January 31, 2022 | January 31, 2021 | January 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-5.49M | $-4.48M | $-6.18M | $-2.93M | $-2.72M |
| Depreciation and Amortization | $287.72K | $368.96K | $318.26K | $169.72K | $91.41K |
| Deferred Income Tax | $- | $- | $- | $-12.93K | $678.77K |
| Stock Based Compensation | $742.70K | $732.13K | $897.83K | $2.00M | $252.70K |
| Change in Working Capital | $223.22K | $-219.32K | $-541.38K | $110.23K | $712.96K |
| Accounts Receivables | $-153.97K | $-41.66K | $42.97K | $-94.75K | $255 |
| Inventory | $60.73K | $-97.69K | $-78.80K | $-10.23K | $-720.15K |
| Accounts Payables | $198.89K | $-104.86K | $-145.26K | $155.22K | $720.15K |
| Other Working Capital | $117.56K | $24.90K | $-360.29K | $59.99K | $712.71K |
| Other Non Cash Items | $704.17K | $614.51K | $2.23M | $363.89K | $91.32K |
| Net Cash Provided by Operating Activities | $-3.53M | $-2.99M | $-2.81M | $-297.06K | $-894.47K |
| Investments in Property Plant and Equipment | $-51.76K | $-79.30K | $-81.59K | $- | $- |
| Acquisitions Net | $- | $- | $- | $66.99K | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-79.30K | $-81.59K | $66.99K | $- |
| Net Cash Used for Investing Activities | $-51.76K | $-79.30K | $-81.59K | $66.99K | $- |
| Debt Repayment | $2.09M | $-17.80K | $-1.63M | $-161.54K | $425.00K |
| Common Stock Issued | $2.61M | $- | $6.42M | $515.11K | $250.00K |
| Common Stock Repurchased | $- | $-119.01K | $-104.47K | $- | $- |
| Dividends Paid | $- | $- | $-196.59K | $- | $- |
| Other Financing Activities | $-1 | $296.88K | $3.14M | $18.31K | $5.25K |
| Net Cash Used Provided by Financing Activities | $2.09M | $160.07K | $7.63M | $371.87K | $430.25K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-252 |
| Net Change in Cash | $-1.49M | $-2.91M | $4.74M | $141.81K | $-464.47K |
| Cash at End of Period | $492.94K | $1.99M | $4.89M | $151.99K | $10.18K |
| Cash at Beginning of Period | $1.99M | $4.89M | $151.99K | $10.18K | $474.65K |
| Operating Cash Flow | $-3.53M | $-2.99M | $-2.81M | $-297.06K | $-894.47K |
| Capital Expenditure | $-51.76K | $-79.30K | $-81.59K | $- | $- |
| Free Cash Flow | $-3.58M | $-3.07M | $-2.89M | $-297.06K | $-894.47K |
Cash Flow Charts
| Breakdown | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 | January 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.36M | $-1.71M | $-1.90M | $-1.88M | $-1.76M | $-829.17K | $-1.02M | $-1.68M | $-1.08M | $-1.04M | $-689.99K | $-3.77M | $-1.57M | $-519.92K | $-315.96K | $-2.25M | $-42.57K | $-225.87K | $-412.19K | $-944.43K |
| Depreciation and Amortization | $73.15K | $69.95K | $69.10K | $69.34K | $52.18K | $83.16K | $83.05K | $70.45K | $112.39K | $93.65K | $92.46K | $82.88K | $79.56K | $79.56K | $76.26K | $76.55K | $47.47K | $22.85K | $22.85K | $22.85K |
| Deferred Income Tax | $- | $- | $- | $322.89K | $- | $- | $-322.89K | $- | $-405.22K | $- | $- | $43.21K | $- | $-3.34K | $-39.88K | $-3.34K | $- | $- | $- | $- |
| Stock Based Compensation | $- | $130.38K | $422.95K | $-499.86K | $580.58K | $- | $162.12K | $- | $405.22K | $- | $- | $610.33K | $529.40K | $97.50K | $127.50K | $1.95M | $12.00K | $38.00K | $- | $-252.70K |
| Change in Working Capital | $-149.76K | $-414.49K | $564.25K | $424.59K | $39.38K | $-260.95K | $20.20K | $-53.45K | $37.43K | $-56.57K | $-146.73K | $-328.25K | $-270.35K | $221.12K | $-163.90K | $52.34K | $82.84K | $52.88K | $-77.83K | $456.24K |
| Accounts Receivables | $-41.62K | $17.13K | $63.51K | $-85.51K | $53.78K | $-70.65K | $-51.60K | $-32.59K | $66.10K | $-47.46K | $-27.72K | $80.03K | $-132.65K | $137.04K | $-41.46K | $-18.69K | $-74.25K | $25.00K | $-26.81K | $59.16K |
| Inventory | $55.56K | $-53.84K | $-1.42K | $6.04K | $-17.72K | $24.58K | $47.84K | $-45.01K | $-22.49K | $-34.30K | $4.12K | $-6.71K | $-52.34K | $17.67K | $-37.42K | $-13.64K | $3.40K | $- | $- | $-29.26K |
| Accounts Payables | $113.33K | $-210.36K | $313.97K | $345.71K | $51.72K | $-244.07K | $9.07K | $- | $-103.70K | $85.42K | $-104.10K | $-2.87K | $-187.05K | $102.68K | $-58.02K | $115.83K | $- | $- | $-59.80K | $-98.57K |
| Other Working Capital | $-277.03K | $-167.43K | $188.19K | $158.35K | $-48.40K | $29.19K | $14.88K | $24.15K | $97.52K | $-60.24K | $-19.03K | $-401.57K | $-85.37K | $66.41K | $-26.99K | $-31.17K | $157.10K | $27.88K | $8.78K | $397.08K |
| Other Non Cash Items | $429.60K | $375.88K | $192.94K | $541.24K | $23.54K | $11.84K | $322.89K | $848.32K | $405.22K | $93.10K | $312.62K | $2.17M | $24.37K | $36.55K | $36.55K | $88.63K | $129.17K | $89.07K | $265.66K | $347.81K |
| Net Cash Provided by Operating Activities | $-1.01M | $-1.54M | $-833.93K | $-718.24K | $-1.06M | $-995.13K | $-749.86K | $-814.00K | $-520.44K | $-908.49K | $-744.26K | $-1.23M | $-1.21M | $-88.53K | $-279.42K | $-83.15K | $99.74K | $-112.14K | $-201.51K | $-117.54K |
| Investments in Property Plant and Equipment | $45.09K | $-38.89K | $-6.20K | $-49.14K | $- | $- | $-2.62K | $-10.02K | $-1.27K | $-24.21K | $-43.80K | $-30.21K | $-1.99K | $-10.62K | $-38.78K | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $66.99K | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-92.04K | $- | $-6.20K | $-51.76K | $- | $- | $- | $- | $- | $- | $-43.80K | $-81.59K | $- | $- | $-38.78K | $66.99K | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-46.96K | $-38.89K | $-6.20K | $-49.14K | $- | $- | $-2.62K | $-10.02K | $-1.27K | $-24.21K | $-43.80K | $-30.21K | $-1.99K | $-10.62K | $-38.78K | $66.99K | $66.99K | $- | $- | $- |
| Debt Repayment | $-5.17K | $-5.14K | $294.92K | $-5.00K | $-4.96K | $2.05M | $45.12K | $-6.61K | $-6.53K | $-692 | $-3.97K | $-106.84K | $-1.51M | $-7.35K | $-6.04K | $-9.25K | $-8.03K | $134.87K | $-279.13K | $25.00K |
| Common Stock Issued | $- | $- | $8.40M | $2.61M | $- | $- | $- | $- | $- | $- | $- | $- | $5.84M | $- | $583.00K | $- | $- | $- | $515.11K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $-240 | $- | $-29.57K | $-89.20K | $-104.47K | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-196.59K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $296.88K | $- | $1.08M | $2.06M | $- | $- | $51.00K | $-4.57K | $-4.13K | $-24.00K | $5.25K |
| Net Cash Used Provided by Financing Activities | $-5.17K | $-5.14K | $8.69M | $-5.00K | $-4.96K | $2.05M | $45.12K | $-6.85K | $-6.53K | $266.61K | $-93.16K | $669.16K | $6.39M | $-7.35K | $576.96K | $41.75K | $-12.59K | $130.74K | $211.98K | $30.25K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $252 |
| Net Change in Cash | $-1.06M | $-1.59M | $7.85M | $-772.38K | $-1.07M | $1.06M | $-707.37K | $-830.88K | $-528.24K | $-666.09K | $-881.22K | $-593.48K | $5.18M | $-106.50K | $258.76K | $-41.40K | $154.14K | $18.60K | $10.46K | $-87.29K |
| Cash at End of Period | $5.70M | $6.76M | $8.35M | $492.94K | $1.27M | $2.33M | $1.28M | $1.99M | $2.82M | $3.34M | $4.01M | $4.89M | $5.49M | $304.26K | $410.75K | $151.99K | $193.39K | $39.25K | $20.64K | $10.18K |
| Cash at Beginning of Period | $6.76M | $8.35M | $492.94K | $1.27M | $2.33M | $1.28M | $1.99M | $2.82M | $3.34M | $4.01M | $4.89M | $5.49M | $304.26K | $410.75K | $151.99K | $193.39K | $39.25K | $20.64K | $10.18K | $97.47K |
| Operating Cash Flow | $-1.01M | $-1.54M | $-833.93K | $-718.24K | $-1.06M | $-995.13K | $-749.86K | $-814.00K | $-520.44K | $-908.49K | $-744.26K | $-1.23M | $-1.21M | $-88.53K | $-279.42K | $-83.15K | $99.74K | $-112.14K | $-201.51K | $-117.54K |
| Capital Expenditure | $-46.96K | $-38.89K | $-6.20K | $-49.14K | $- | $- | $-2.62K | $-10.02K | $-1.27K | $-24.21K | $-43.80K | $-30.21K | $-1.99K | $-10.62K | $-38.78K | $- | $- | $- | $- | $- |
| Free Cash Flow | $-1.06M | $-1.58M | $-840.12K | $-767.38K | $-1.06M | $-995.13K | $-752.49K | $-824.03K | $-521.72K | $-932.70K | $-788.06K | $-1.26M | $-1.21M | $-99.15K | $-318.19K | $-83.15K | $99.74K | $-112.14K | $-201.51K | $-117.54K |
Nutriband Dividends
Explore Nutriband's dividend history, including dividend yield, payout ratio, and historical payments.
Nutriband News
Read the latest news about Nutriband, including recent articles, headlines, and updates.
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.
Nutriband Signs Partnership Agreement with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™.
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. ORLANDO, Fla.
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology.
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025.
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024.
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application entitled, “Abuse and Misuse Deterrent Transdermal Systems,” which protects its AVERSA™ abuse deterrent transdermal technology.
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica ORLANDO, FL / ACCESSWIRE / October 17, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has received approval from the Costa Rica Ministry of Health for the production and marketing of its Mosquito Repellent Patch, designed to reduce the risk of mosquito bites and associated health risks associated with exposure to mosquito bites.
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the Company's current operations and upcoming milestones.
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch ORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China.
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products ORLANDO, FL / ACCESSWIRE / September 20, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed a trademark licensing agreement for the use of Bitrex® brand denatonium benzoate as an aversive agent in its lead product, AVERSA™ Fentanyl, an abuse deterrent fentanyl patch. Nutriband's AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
Nutriband Inc. Authorizes $1M Share Buyback Program
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding.
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has reported its financial results for the second quarter ended July 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for the first half of 2025.
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Chairman and President Serguei Melnik and Chief Executive Officer Gareth Sheridan, who will share insight into the Company's current operations and upcoming milestones.
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 9, 2024, for trademark application Serial Number 98117984, covering the mark "AVERSA™." The Notice of Allowance signifies that the USPTO is expected to grant a trademark registration for this application following the completion of administrative processes.
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to NDA filing. As previously reported, the Company with its partner Kindeva Drug Delivery completed the feasibility agreement and entered into a commercial development and clinical supply agreement to manufacture product for the human abuse potential clinical study in support of a New Drug Application (NDA) to be submitted to FDA.
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life Group, who hold licenses for major international brands such as Reebok, Adidas and New Balance.
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement ORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m.
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive Supplier agreement for FFL's new product launch under one of their top brands. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer.
Nutriband Inc. Announces $8.4M Private Placement
Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 2,100,000 shares of common stock (the "Shares"), at a purchase price of $4 per share of common stock; for each Share of common stock purchased the investor receives a five-year warrant to purchase two shares of common stock. The exercise price of the Warrants is $6.43 per share.
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer abuse-deterrent transdermal patches ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure was presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting on March 8, 2024. The American Academy of Pain Medicine (AAPM) is dedicated to advancing multidisciplinary pain care, education, advocacy, and research.
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Scottsdale, Arizona March 7-10, 2024. The company engaged Rocky Mountain Poison & Drug Safety (RMPDS), a division of Denver Health and Hospital Authority, Denver, Colorado to determine the incidence of abuse and accidental pediatric exposure of transdermal patches containing drugs of abuse in the United States.
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st. ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference taking place January 30th through February 1 in Caesars Atlantic City.
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The full text of the letter is below.
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence (AI Tape) Brand portfolio. AI Tape Heating and Cooling provides all of the stretch, support, and benefits of traditional kinesiology tape, plus pain-relieving ingredients that provide both heating and cooling sensation for the temporary relief of minor aches and pains of muscles and joints.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NTRB.